US Stock Insider Trading | CeriBell disclosed 4 insider transactions on February 5

K-LinePoet · 2026-02-25T08:25:33+00:00

CeriBell disclosed four insider transactions on February 5, 2026, including buying and selling records of executives Foehr David and Woo Raymond. CeriBell focuses on rapid diagnosis and management of neurological diseases, developing an innovative EEG platform aimed at improving patient prognosis and economic benefits.

K-LinePoet

2026-02-25 08:25:33

Abstract generation in progress

On February 5, 2026, CeriBell (CBLL) disclosed four insider transactions. Executive Foehr David sold 3,403 shares on February 3, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 5, 2026	Executive	Foehr David	February 3, 2026	Sell	5,556	20.00	$111,100
February 5, 2026	Executive	Foehr David	February 3, 2026	Buy	5,556	4.70	$26,122
February 4, 2026	Executive	Woo Raymond	February 2, 2026	Sell	4,497	20.57	$92,477
February 4, 2026	Executive	Woo Raymond	February 2, 2026	Buy	9,640	4.70	$45,358
February 4, 2026	Executive	Woo Raymond	February 2, 2026	Sell	6,615	20.54	$135,859
February 4, 2026	Executive	Woo Raymond	February 2, 2026	Buy	1,472	2.24	$3,297.28
January 20, 2026	Director	Parvizi Josef	January 15, 2026	Sell	25,000	22.94	$573,500
January 12, 2026	Executive	Manni Joseph S.	November 20, 2025	Sell	660	13.64	$9,002.40
January 7, 2026	Executive	Foehr David	November 20, 2025	Sell	484	13.64	$6,601.76
January 7, 2026	Executive	Foehr David	January 5, 2026	Buy	5,556	4.70	$26,122

[Company Profile]

CeriBell, Inc. was incorporated in Delaware on August 29, 2014. They are a clinical-stage medical technology company focused on transforming the diagnosis and management of severe neurological diseases. They developed the Ceribell system, a novel point-of-care EEG platform designed to meet unmet needs in acute care settings. The Ceribell system combines proprietary, highly portable, rapidly deployable hardware with complex AI-driven algorithms to enable rapid diagnosis and continuous monitoring of neurological patients. By harnessing AI, the Ceribell system makes EEG more accessible and allows for continuous monitoring, enabling clinicians to diagnose and manage patients at risk of seizures more quickly and accurately in acute care environments, ultimately improving patient outcomes and economic benefits for hospitals and payers.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.